VP01 Emerging Drug Insight

“VP01 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about VP01 for Progressive Fibrosing Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis in the seven major markets. A detailed picture of the VP01 in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, for the study period 2019 –2032 is provided in this report, along with a detailed description of the VP01. The report provides insights about VP01's Mechanism of Action, dosage, and administration, as well as research and development, including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, inclusive of the VP01 market forecast analysis in the 7MM, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies.

VP01 Drug Summary

C21 (VP01 program) is a first-in-class, small-molecule activator of angiotensin II receptor type 2 (AT2R), a protein receptor whose activation promotes blood vessel widening and prevents tissue scarring, or fibrosis, by activating the “protective arm” of the renin-angiotensin system, being developed by Vicore. The positive characteristics of C21 are supported by extensive preclinical research. Vicore has focused the development of C21 on fibrotic lung diseases, where preclinical studies have indicated that C21 may affect Idiopathic Pulmonary Fibrosis (IPF) and related indications.

By activating AT2R, C21 is designed to improve blood flow and reduce the formation of scar tissue in the lungs, ultimately slowing or preventing further IPF progression. In Phase II, the safety, pharmacokinetics, and effectiveness of C21 are being evaluated in the UK, India, Ukraine, and Russia. An interim analysis of the trial suggests that C21 stabilizes disease and increases lung function in patients with IPF.

VP01 Market Forecast Report Scope

The report provides insights into:

• A comprehensive VP01 Product overview including the VP01 description, VP01 mechanism of action, dosage and administration, research and development activities in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• Elaborated details on VP01 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VP01 research and development activities in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) across the United States, Europe and Japan.
• The VP01 Market Forecast Report also covers the patent information with expiry timeline around VP01.
• The report contains forecasted VP01 Sales for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• The VP01 Market Forecast Report also features the SWOT analysis with analyst views for VP01 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).

VP01 Methodology

The VP01 Market Size Report is built using data and information sourced primarily from internal databases, primary and secondary research, and in-house analysis by DelveInsight’s team of industry experts. Information and VP01 Sales Data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

VP01 Market Analytical Perspective by DelveInsight

In-depth VP01 Market Assessment

This report provides a detailed market assessment of VP01 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan. This segment of the report provides forecasted VP01 sales data.

VP01 Clinical Trials Assessment

The report provides the VP01 Clinical Trials information for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF), covering trial interventions, trial conditions, trial status, start, and completion dates.

VP01 Market Forecast Report Highlights

• In the coming years, the VP01 Market scenario for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug VP01 manufacturers to penetrate more into the market.  
• The VP01 Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VP01 dominance.
• Other emerging VP01 Products for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) are expected to give tough market competition to VP01 and launch of late-stage emerging therapies shortly will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of VP01 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• Our in-depth analysis of the forecasted VP01 Sales Data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VP01 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• Analyze VP01 Cost, pricing trends, and market positioning to support strategic decision-making in the VP01 Market Landscape.

Key Questions

• What is the VP01 Product type, route of administration, and VP01 Mechanism of Action?
• What is the VP01 Clinical Trials status of the study related to Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the VP01 development?
• What are the key designations that have been granted to VP01 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?
• What is the forecasted market scenario of VP01 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?
• What are the forecasted VP01 Sales in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging VP01 Products available, and how are these giving competition to VP01 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?
• Which are the late-stage emerging therapies under development for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?

Stay updated with us for Recent Articles @ Latest DelveInsight Blogs